Edition:
United States

Agenus Inc (AGEN.PH)

AGEN.PH on Philadelphia Stock Exchange

3.74USD
21 Nov 2017
Change (% chg)

-- (--)
Prev Close
$3.74
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
11,660
52-wk High
$5.41
52-wk Low
$3.20

Latest Key Developments (Source: Significant Developments)

Agenus reports Q3 loss per share $0.37
Tuesday, 7 Nov 2017 09:22am EST 

Nov 7 (Reuters) - Agenus Inc :Agenus reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.37.Q3 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S.Agenus Inc - ‍Cash, cash equivalents and short-term investments were $70.1 million at Sept 30, 2017 compared to $76.4 million as of Dec 31, 2016​.Agenus Inc - Qtrly revenue $3.4 million versus $4.4 mln‍​.  Full Article

Agenus files for mixed shelf of up to $250 million
Wednesday, 18 Oct 2017 06:14pm EDT 

Oct 18 (Reuters) - Agenus Inc :Agenus Inc files for mixed shelf of up to $250 million – SEC filing‍​.  Full Article

Agenus Inc Q2 loss per share $0.32
Thursday, 3 Aug 2017 08:50am EDT 

Aug 3 (Reuters) - Agenus Inc :Agenus reports second quarter 2017 financial results and provides corporate update.Q2 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S.Q2 loss per share $0.32.Cash, cash equivalents and short-term investments were $96.8 million at June 30, 2017 compared to $76.4 million as of december 31, 2016​.Qtrly ‍revenue $ 4.2 million versus $ 6.6 million.Q2 revenue view $5.0 million -- Thomson Reuters I/B/E/S.  Full Article

Agenus Q1 loss per share $0.18
Thursday, 4 May 2017 08:50am EDT 

May 4 (Reuters) - Agenus Inc ::Agenus reports first quarter 2017 financial results and provides corporate update.Q1 loss per share $0.18.Q1 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.Qtrly revenue $27 million versus $ 6 million.Agenus Inc - plans to pursue its cell therapy assets with formation of a separate business entity to be majority owned by agenus and funded externally.  Full Article

Phase 1/2 clinical trial of Agenus' anti-PD-1 antibody begins
Thursday, 20 Apr 2017 08:50am EDT 

April 20 (Reuters) - Agenus Inc :Phase 1/2 clinical trial of Agenus' anti-PD-1 antibody begins.Agenus Inc - Preliminary safety and efficacy data are expected to be available within next 9-12 months from AGEN2034 study.  Full Article

Agenus commences phase 1 trial with neoantigen cancer vaccine autosynvax
Wednesday, 5 Apr 2017 08:50am EDT 

Agenus Inc : Agenus commences phase 1 trial with neoantigen cancer vaccine autosynvax .Agenus Inc - preclinical data presented at AACR 2017 annual meeting show ASV to be active and synergistic with checkpoint blockade.  Full Article

Agenus says plans to close Basel site, combine key functions to Cambridge, UK and Lexington, MA facilities
Thursday, 30 Mar 2017 06:45am EDT 

Agenus Inc : Agenus restructures business to sharpen focus on clinical development of cancer therapies . Agenus - plans to close Basel site, consolidate key functions to Cambridge, UK and Lexington, MA facilities, and phase out approximately 50 positions . Agenus Inc - Robert Stein, M.D., Ph.D., president of research and development, will retire to become a senior research and development advisor exclusive to Agenus .Says as part of restructuring, approximately 50 positions are planned to be phased out within next six months.  Full Article

QVT Financial reports 5.08 pct passive stake in Agenus
Friday, 3 Feb 2017 05:03pm EST 

Agenus Inc :QVT Financial Lp reports a 5.08 percent passive stake in Agenus Inc as of January 24, 2017 - sec filing.  Full Article

Agenus files for offering of up to 157,513 shares by selling stockholder
Friday, 20 Jan 2017 04:21pm EST 

Agenus Inc :Files for offering of up to 157,513 shares of co's common stock by the selling stockholder - SEC filing.  Full Article

Agenus Q2 loss per share $0.33
Thursday, 28 Jul 2016 08:50am EDT 

Agenus Inc : Qtrly revenue $6.6 million versus $6.4 million . Agenus reports second quarter 2016 financial results and operational progress . Q2 loss per share $0.33 . Q2 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S .Q2 revenue view $5.1 million -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Agenus reports Q3 loss per share $0.37

* Agenus reports third quarter 2017 financial results and provides corporate update